Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Just Scratching the Surface cover art

Just Scratching the Surface

Just Scratching the Surface

Written by: Kaleb Abbott and Andrew Pucker
Listen for free

About this listen

Conversations on ocular surface disease care that address real-world clinical questions, hosted by optometrists Kaleb Abbott and Andrew Pucker with a new guest expert each episode. Updated monthly.

Kaleb Abbott, Andrew Pucker
Biological Sciences Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • Industry Insights: A Career in Medical Affairs
    Nov 3 2026

    In this episode, Drs. Abbott and Pucker speak with Mina Chang, OD, an optometrist who left clinical practice five years ago for the pharmaceutical industry. Dr. Chang has served as a Medical Science Liaison (MSL) in both glaucoma and dry eye, and recently was promoted to Senior Manager of Medical Affairs at Alcon.

    Dr. Chang explains that she stumbled into industry almost by accident during a casual lunch conversation about what an MSL does. She encourages listeners not to be discouraged by setbacks in the job pursuit process, noting that networking—reaching out to strangers on LinkedIn, chatting with medical affairs representatives at conference booths—is often more valuable than submitting applications into the void.

    The conversation then digs into what an MSL actually does: serving as a scientific bridge between pharmaceutical companies and clinicians, sharing data on mechanisms of action and disease states and funneling field insights back to the company to inform research gaps or real-world post-market studies. Dr. Chang is careful to distinguish this from sales—MSLs operate under strict regulatory "firewalls" that prevent them from promoting products. Rather, their job is to present balanced, credible science and let clinicians draw their own conclusions, which she describes as roughly half scientific expertise and half relationship-building.

    Dr. Chang also reflects on the texture of daily life in industry: packed weeks of travel, back-to-back meetings (sometimes at odd hours), dinner events intruding on personal time and a more fluid schedule than she had as a clinician. That schedule was one of the hardest adjustments, she explains—moving from the structured, patient-driven rhythm of the clinic to a more strategy-oriented role required a real mindset shift. Dr. Chang candidly discusses missing the small, frequent rewards of clinical care; while industry work can have a much larger scale of impact—reaching thousands of clinicians and, by extension, their patients—those wins come far less often, sometimes only once or twice a year, compared to the daily satisfaction of helping patients in clinic.

    Switching between therapeutic areas, as Dr. Chang did between glaucoma and dry eye, meant learning an entirely new scientific landscape and set of key opinion leaders each time, though the foundational skills of an MSL—translating data, building trust, delivering education—stayed consistent. She also walks through what a drug launch looks like from the medical affairs side, noting that preparation typically begins 12 to 18 months in advance, running parallel to late-stage clinical trials and FDA review.

    Looking back, Dr. Chang says she wouldn't change her path, though she wishes she'd known earlier about opportunities like OD internships with industry. She closes by encouraging curious optometrists to network persistently, emphasizing that credentials and polish matter less than adaptability, curiosity, and genuine interest in the field.

    Show More Show Less
    36 mins
  • DEWS III Decoded: What Clinicians Need to Know
    Sep 30 2026

    Hosts Kaleb Abbott and Andrew Pucker welcome renowned ophthalmologist Penny Asbell to discuss the key updates from the recently published TFOS DEWS III report, the latest international consensus document on dry eye disease. The report spans over 300 pages and cites more than 1,000 references, making it extremely comprehensive but not very user-friendly for busy doctors who want to absorb the key points. Dr. Asbell—one of the authors—is here to help.

    The conversation begins with the updated definition of dry eye disease. While DEWS III’s version is similar to the DEWS II definition, the key change is an expanded concept of homeostasis, which now encompasses not just the tear film but also the ocular surface more broadly. The etiological factors listed include tear film instability, hyperosmolarity, ocular surface inflammation and damage and neurosensory abnormalities.

    Next, the three doctors unpack the OSDI-6 patient questionnaire, a streamlined six-question version of the original 12-question form. Covering symptoms, activity limitations and environmental triggers, it is scored from 0-24, with scores of four or above indicating significant dry eye. The hosts and Dr. Asbell agree it is an easy, efficient screening tool suitable for routine clinical use.

    The group then discusses the role of inflammation in dry eye, with Dr. Asbell noting that while DEWS III emphasizes inflammation as a key factor, her own experience, including data from the somewhat controversial NIH-funded DREAM trial, suggests it is not universal across all dry eye patients. She expresses hope that improved ocular biomarkers will eventually help clinicians better identify which patients have meaningful inflammation and would benefit most from anti-inflammatory therapies.

    The conversation also addresses the report’s expanded focus on eyelid abnormalities, including blink mechanics and incomplete lid closure, topics that Dr. Asbell notes were championed by dry eye guru Donald Korb decades ago. The trio share practical clinical tips for identifying nocturnal lagophthalmos, including the Korb-Blackie light test, and discuss often-overlooked causes such as blepharoplasty and Botox use.

    Regarding disease classification, DEWS III moves beyond the traditional aqueous-deficient vs. evaporative binary, instead organizing dry eye into three categories: tear film deficiencies, eyelid abnormalities and ocular surface abnormalities. This framework forms the basis of the DEWS III approach to treatment, providing a structure that can allow for a streamlined approach.

    The episode ends with thoughts on dry eye treatment, with notable discussions including semi-fluorinated alkanes (Miebo), hyaluronic acid lubricants, corticosteroids, tacrolimus ointment and regenerative therapies such as autologous serum. Dr. Asbell also raises important questions about the quality of evidence supporting certain devices and procedures, noting the difficulty of running well-controlled clinical trials in dry eye, given the highly subjective experience of patients.

    Relevant Articles:

    TFOS DEWS III Treatment Report Details Full Panoply of Interventions

    Simplifying the Diagnosis of Dry Eye Disease

    TFOS DEWS III Refines Key Diagnostic Protocols, Emphasizes Importance of Subtyping

    Show More Show Less
    43 mins
  • The Leap from Clinic to Industry
    Sep 1 2026

    This episode, Drs. Abbott and Pucker begin an occasional series called “Industry Insights,” welcoming guest Natalie Nguyen, OD, Senior Director of Medical Affairs at Harrow, to discuss what it’s like for optometrists to transition from clinical practice into the pharmaceutical industry.

    Dr. Nguyen, a Memphis native who completed her optometry degree at Southern College of Optometry, made the leap in 2022. She first learned about industry careers around 2017 through a pharmaceutical representative who introduced her to the Medical Science Liaison (MSL) role, a career path she hadn't known existed, as it was never discussed during her optometry training. She explains that her motivation to transition wasn’t burnout, as might be expected, but rather a growing curiosity about the science and strategy behind patient care—a desire to influence outcomes on a larger scale than one-on-one clinical encounters allow.

    A significant portion of the conversation focuses on demystifying the MSL role. Dr. Nguyen characterizes the MSL role as a scientific bridge between a pharmaceutical company and the medical community—a non-promotional position involving peer-to-peer scientific discussions with clinicians that supports medical education. An important responsibility is bringing field insights back to the company internally. The role demands significant travel (50% to 80%), a high degree of autonomy and a broad skill set that goes well beyond scientific knowledge, she explains, including relationship-building, emotional intelligence, adaptability and self-discipline.

    Dr. Nguyen talks candidly about the challenges of breaking into industry, sharing that she was rejected by three or four companies before landing her position at Harrow through a LinkedIn posting. She emphasizes that the field is increasingly competitive, and that a clinical background alone is no longer sufficient—candidates must find ways to differentiate themselves. Once hired at Harrow, she faced the additional challenge of being the company's first-ever medical affairs employee, essentially building the function from the ground up without formal onboarding or mentorship.

    Her career advanced rapidly from MSL to Field Medical Director to her current role as Senior Director of Medical Affairs, where she oversees scientific strategy, cross-functional alignment, and long-term planning within the medical affairs function.

    For optometrists considering a similar path, Dr. Nguyen’s key advice includes: do thorough research on the role and company, build genuine relationships through networking, find mentors early, embrace discomfort and never burn bridges in what is a surprisingly small professional community. She closes by saying that, given everything she knows now, she would make the same career leap without hesitation.

    Show More Show Less
    34 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet